| Why Conmed (CNMD) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-02 14:46:04 |
Czytaj oryginał (ang.) |
| CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook |
CNMD reports solid first-quarter results, driven by improving sales across both segments. |
zacks.com |
2025-05-01 14:15:47 |
Czytaj oryginał (ang.) |
| CONMED Corporation (CNMD) Q1 2025 Earnings Call Transcript |
CONMED Corporation (NYSE:CNMD ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer and President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Robbie Marcus - JPMorgan Rick Wise - Stifel Young Li - Jefferies Travis Steed - Bank of America Mike Matson - Needham Operator Good day, and thank you for standing by. Welcome to CONMED's First Quarter Fiscal 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-01 01:52:06 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-01 00:05:34 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates |
Conmed (CNMD) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.79 per share a year ago. |
zacks.com |
2025-04-30 23:01:13 |
Czytaj oryginał (ang.) |
| 4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind |
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD. |
zacks.com |
2025-04-14 15:10:45 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain CONMED Stock in Your Portfolio for Now |
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks. |
zacks.com |
2025-04-08 11:50:34 |
Czytaj oryginał (ang.) |
| CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025 |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro. |
businesswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| CONMED Corporation Adds Mark Kaye to its Board of Directors |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcome Mark to the board,” said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. “Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a stro. |
businesswire.com |
2025-02-25 09:03:00 |
Czytaj oryginał (ang.) |
| CONMED Corporation Announces Quarterly Cash Dividend |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, includ. |
businesswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for February 19th |
ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024. |
zacks.com |
2025-02-19 08:15:24 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for February 11th |
ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025. |
zacks.com |
2025-02-11 08:15:21 |
Czytaj oryginał (ang.) |
| CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook |
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product. |
zacks.com |
2025-02-06 12:46:30 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings |
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-05 21:36:09 |
Czytaj oryginał (ang.) |
| CONMED Corporation (CNMD) Q4 2024 Earnings Call Transcript |
CONMED Corporation (NYSE:CNMD ) Q4 2024 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer & President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Corporate & Investment Banking Young Li - Jefferies Travis Steed - BofA Securities Operator Thank you for standing by, and welcome to CONMED's Fourth Quarter Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives. |
seekingalpha.com |
2025-02-05 21:05:16 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates |
Conmed (CNMD) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.06 per share a year ago. |
zacks.com |
2025-02-05 20:25:25 |
Czytaj oryginał (ang.) |
| CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted n. |
businesswire.com |
2025-02-05 18:05:00 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Earnings Expected to Grow: Should You Buy? |
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-29 13:06:21 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy CONMED (CNMD) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-08 12:46:48 |
Czytaj oryginał (ang.) |
| CONMED Corporation to Announce Fourth Quarter 2024 Financial Results on February 5, 2025 |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2024 after the market close on Wednesday, February 5, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed. |
businesswire.com |
2025-01-06 18:16:00 |
Czytaj oryginał (ang.) |
| CONMED Corporation to Present at the J.P. Morgan Healthcare Conference |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan Healthcare Conference at 4:30 p.m. PT (7:30 p.m. ET) on Monday, January 13, 2025 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.conmed.com and will be ava. |
businesswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| CNMD vs. ALGN: Which Stock Is the Better Value Option? |
Investors interested in Medical - Dental Supplies stocks are likely familiar with Conmed (CNMD) and Align Technology (ALGN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-01-02 14:46:33 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain CONMED Stock in Your Portfolio for Now |
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks. |
zacks.com |
2024-12-30 10:15:25 |
Czytaj oryginał (ang.) |
| Here's Why Conmed (CNMD) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-12-11 12:46:11 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain CONMED Stock in Your Portfolio for Now |
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks. |
zacks.com |
2024-11-29 11:55:14 |
Czytaj oryginał (ang.) |
| Here's Why Conmed (CNMD) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-27 12:40:36 |
Czytaj oryginał (ang.) |
| Why Conmed (CNMD) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-25 12:50:34 |
Czytaj oryginał (ang.) |
| CONMED Corporation to Participate in a Fireside Chat at the Piper Sandler Healthcare Conference |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat J. Beyer, Chief Operating Officer, will participate in a fireside chat at the Piper Sandler Healthcare Conference at 12:30 p.m. ET on Tuesday, December 3, 2024. A live video webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at. |
businesswire.com |
2024-11-18 18:05:00 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-15 12:51:24 |
Czytaj oryginał (ang.) |
| Why Conmed (CNMD) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-11 12:41:12 |
Czytaj oryginał (ang.) |
| Here's Why Conmed (CNMD) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-08 12:46:14 |
Czytaj oryginał (ang.) |
| CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View |
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses. |
zacks.com |
2024-10-31 11:46:26 |
Czytaj oryginał (ang.) |
| CONMED Corporation (CNMD) Q3 2024 Earnings Call Transcript |
CONMED Corporation (NYSE:CNMD ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Curt Hartman – Chairman, President and Chief Executive Officer Pat Beyer – Chief Operating Officer Todd Garner – Executive Vice President and Chief Financial Officer Conference Call Participants Kristen Stewart – C.L. King Lily Delaney – JPMorgan Dino Weinstock – Wells Fargo Operator Good day and thank you for standing by. |
seekingalpha.com |
2024-10-30 23:21:02 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say |
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-10-30 22:01:14 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Surpasses Q3 Earnings Estimates |
Conmed (CNMD) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.90 per share a year ago. |
zacks.com |
2024-10-30 21:21:18 |
Czytaj oryginał (ang.) |
| CONMED Corporation Announces Third Quarter 2024 Financial Results |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Sales of $316.7 million increased 4.0% year-over-year as reported and 4.3% in constant currency. Diluted net earnings per share (GAAP) were $1.57 compared to diluted net earnings per share (GAAP) of $0.50 in the third quarter of 2023. Adjusted diluted net earnings per share(1) were $1.05, an increase of 16.7% compared to th. |
businesswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| CONMED Corporation Announces Leadership Succession |
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman will retire as President and Chief Executive Officer (CEO) of the Company, effective January 1, 2025. Patrick Beyer, current Chief Operating Officer (COO) of CONMED, will succeed Mr. Hartman as President and CEO and will also be appointed as a member of the Company's board, effective the same date. As part of the transition, Lead Independent Director Martha Goldberg Aronson will assume the positio. |
businesswire.com |
2024-10-30 18:02:00 |
Czytaj oryginał (ang.) |
| Conmed (CNMD) Earnings Expected to Grow: Should You Buy? |
Conmed (CNMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-23 15:07:47 |
Czytaj oryginał (ang.) |
| Here's Why Conmed (CNMD) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-10-23 14:46:24 |
Czytaj oryginał (ang.) |
| Will Conmed (CNMD) Beat Estimates Again in Its Next Earnings Report? |
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-10-14 17:11:22 |
Czytaj oryginał (ang.) |